Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (HK:1801)
HKEX:1801
Holding HK:1801?
Track your performance easily
1801 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$28.30 - HK$49.80
Previous CloseHK$42.15
Volume10.67M
Average Volume (3M)5.85M
Market Cap
HK$68.75B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 26, 2025EPS Estimate
-HK$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares OutstandingN/A
10 Day Avg. Volume5,189,904
30 Day Avg. Volume5,845,918
Standard Deviation0.17
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$56.36Price Target Upside33.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Innovent Biologics News
PremiumCompany Announcements
Innovent Biologics Grants Shares to Employees
PremiumCompany Announcements
Innovent Biologics Announces Board Reshuffle
PremiumCompany Announcements
Innovent Biologics Reveals Board and Committee Structure
PremiumCompany Announcements
Innovent Biologics Reports H1 2024 FinancialsPremiumCompany Announcements
Innovent Biologics Unveils Breakthrough Lung Cancer Drug
PremiumCompany Announcements
Innovent Biologics Schedules Critical Financial Meeting
PremiumCompany Announcements
Innovent Biologics Announces Soaring Q2 Revenue Growth
PremiumCompany Announcements
Innovent Biologics’ Diabetes Drug Nears China MarketOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
11.47% Mutual Funds
6.93% Other Institutional Investors
81.60% Public Companies and
Individual Investors
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$28.30 and its highest was HK$49.80 in the past 12 months.
What is Innovent Biologics’s market cap?
Currently, no data Available
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Mar 26, 2025 which is in 187 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 28, 2024. The company reported -HK$0.264 earnings per share for the quarter, beating the consensus estimate of -HK$0.275 by HK$0.011.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is -HK$0.33.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,631,045,900 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of -HK$0.264 in its last earnings report, beating expectations of -HK$0.275. Following the earnings report the stock price went down -0.451%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
---
Innovent Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$56.36 (33.72% Upside)
HK$56.36 (33.72% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.28%
12-Months-Change
Fundamentals
Return on Equity
-11.09%
Trailing 12-Months
Asset Growth
13.37%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. is an investment company, which engages in the development and manufacture of biopharmaceutical products. Its products include sintilimab (IBI-308), a novel PD-1 antibody; IBI-305, the bevacizumab (Avastin) biosimilar; IBI-301, the rituximab (MabThera/Rituxan) biosimilar; and IBI-303, the (Humira) biosimilar. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
---
1801 Stock 12 Month Forecast
Average Price Target
HK$56.36
▲(33.72% Upside)
Technical Analysis
Best Analysts Covering 1801
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+9.01%
reiterated a buy rating 23 days ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +9.01% per trade.
---